Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
sage-10k_20191231.htm
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
sage-10k_20161231.htm
sage-10k_20181231.htm
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage advice: psychiatric drug development is tough | Evaluate
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage advice: psychiatric drug development is tough | Evaluate
